Novartis, Celgene Hit Teva Again Over ADHD Drug Patents

Law360, New York (December 8, 2011, 5:51 PM EST) -- Celgene Corp. and Novartis AG recently hit Teva Pharmaceuticals USA Inc. with a fresh patent infringement suit in New Jersey over Teva’s plan to market a generic version of attention deficit hyperactivity disorder drug Focalin XR, the latest in a long-running battle between the companies.

The plaintiffs claim the suit, filed Dec. 2, was prompted by Teva USA, the American unit of Israel-based Teva Pharmaceutical Industries Ltd., which updated an Abbreviated New Drug Application filed with the U.S. Food and Drug Administration, adding 25-mg and 35-mg...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.